AZN CHMP opinion: Thursday, July 23, 2026

Variation type II · Saphnelo · Update of sections 4.4, 4.8, and 5.1 of the SmPC in order to add new safety and efficacy data, based on final results from the TULIP SC study (D3465C00001); this is a Phase III, randomized, double-blind, multicenter, parallel-group, placebo-controlled study to evaluate

Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.